Corvus Pharmaceuticals, Inc. balance sheet CRVS

Annual Quarterly

As of Sep 30, 2026, Corvus Pharmaceuticals, Inc. had total assets of $223.9 million and total liabilities of $15.6 million. Total assets were up 178.2% from a year earlier. Stockholders' equity was $208.3 million. It held $202.9 million in cash and investments against $632,000 of total debt, net cash of $202.3 million. The current ratio, current assets divided by current liabilities, was 13.38.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Assets
Cash
15
+423.6%
19
+28.7%
40
+702.2%
5
-47.6%
3
-38.7%
15
-1.0%
5
-33.0%
9
-30.7%
Short-term investments
188
196
197
52
—
—
—
—
Cash and investments
203
+208.9%
215
+189.3%
237
+435.4%
57
+9.2%
66
+57.7%
74
+57.5%
44
+99.8%
52
+91.4%
Receivables
0
-84.4%
0
-93.0%
0
-45.6%
0
-50.7%
0
-54.3%
0
+145.7%
0
+203.8%
0
+188.5%
Total current assets
206
+208.2%
221
+191.6%
240
+427.5%
58
+7.0%
67
+56.0%
76
+57.0%
45
+99.1%
54
+94.6%
Property and equipment, net
1
+262.4%
1
+233.3%
0
+70.9%
0
+45.7%
0
+29.2%
0
+29.7%
0
-22.5%
0
-36.0%
Total assets
224
+178.2%
239
+167.5%
253
+326.0%
71
+3.2%
80
+36.8%
89
+38.6%
59
+48.3%
69
+51.3%
Liabilities and equity
Accounts payable
6
+186.0%
4
+29.0%
5
+259.1%
2
-3.5%
2
+5.4%
3
+158.6%
1
-18.7%
3
+69.3%
Total current liabilities
15
+91.0%
14
+60.8%
12
+30.5%
9
-73.5%
8
-82.6%
9
-36.2%
9
+38.1%
35
+415.4%
Total liabilities
16
+78.7%
14
+51.0%
13
+23.8%
10
-72.7%
9
-81.2%
9
-30.8%
10
+50.5%
36
+429.0%
Stockholders' equity
208
+190.3%
225
+180.9%
241
+387.9%
61
+87.9%
72
+478.4%
80
+56.6%
49
+47.8%
33
-15.8%
Debt
Lease liabilities
1
-37.5%
1
-32.8%
1
-27.7%
1
-16.5%
1
+185.6%
1
+54.7%
1
+10.9%
1
-59.2%
Total debt
1
-37.5%
1
-32.8%
1
-27.7%
1
-16.5%
1
+185.6%
1
+54.7%
1
+10.9%
1
-59.2%
Net cash
202
+212.8%
214
+192.5%
236
+447.8%
56
+9.8%
65
+56.6%
73
+57.5%
43
+104.2%
51
+108.4%
Ratios
Current ratio
13.38x
16.16x
19.81x
6.21x
8.29x
8.91x
4.90x
1.54x
Debt to equity
0.00x
0.00x
0.00x
0.02x
0.01x
0.01x
0.02x
0.03x
Return on equity
-30.87%
-24.02%
-18.35%
-24.97%
-21.01%
-56.26%
-83.93%
-191.27%
Return on assets
-28.73%
-22.62%
-17.44%
-21.49%
-18.73%
-50.45%
-69.65%
-90.40%
Book value per share
2.47
2.68
2.86
0.82
0.96
1.08
0.72
0.48
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CRVS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1626971

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.